Pathstone Holdings
COGT icon

Pathstone Holdings’s Cogent Biosciences COGT Stock Holding History

Pathstone Holdings’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-17,599
Closed -$103K – 2308
2023
Q4 		$103K Buy
+17,599
New +$135K ﹤0.01% 2145

Other funds holding COGT

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Pathstone Holdings's COGT Position: Q1 2024 in Review

Pathstone Holdings sold out of Cogent Biosciences (COGT) in Q1 2024, closing a stake of 17,599 shares — an estimated $103K sold.

Pathstone Holdings first reported a position in COGT in Q4 2023 and held it in 1 quarter. The position peaked at $103K in Q4 2023. 146 funds tracked by Wall St. Rank hold COGT as of Q1 2024.

  • Pathstone Holdings reported no remaining Cogent Biosciences position as of Q1 2024 after selling out during the quarter.
  • Pathstone Holdings sold 17,599 Cogent Biosciences shares in Q1 2024, an estimated $103K.
  • Pathstone Holdings first reported a position in Cogent Biosciences in Q4 2023 and held it in 1 quarter.
  • Pathstone Holdings's Cogent Biosciences position peaked at $103K in Q4 2023.
  • 146 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2024.

Based on Pathstone Holdings's 13F filing for Q1 2024, filed 13 May 2024.